4SC has reported progress with both its clinical-stage assets – resminostat, a broad spectrum HDAC inhibitor, and domatinostat, a specific Class…
Stifel Nicolaus Europe Limited
Phone: +44(0)20 7710 7495
Phone: +44 (0) 20 7710 7606
London EC2V 6ET
|06 July 2018||Initiation Report||4SC AG (VSC – XETRA; VSCk.DE)|
LifeSci Capital LLC
250 West 55th Street, 34th Floor
New York, NY 10019
Phone: +1 212 915 2573
|09 August 2018||Company Update||4SC AG (VSC.F): 4SC Reported Q2 and H1 2018 Financials and Provided Timelines for its Clinical Studies|
|03 July 2018||Company Update||4SC AG (VSC.F): SRC Recommends Phase Ib/II Study with Domatinosat Continue; Results from Multiple Cohorts Coming in H2 2018|
|29 June 2018||Initiation Report||4SC AG (VSC.F)|
goetzpartners securities Limited
Chris Redhead, Ph.D.
The Stanley Building
7 Pancras Square
London N1C 4AG
Phone: +44 (0) 20 3859 7725
goetzpartners research reports are intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
|09 August 2018||Company Note||4SC AG (VSC-DE): On track and undervalued|
|16 July 2018||Company Note||4SC AG (VSC-DE): Melanoma data major catalyst in second half|
|5 April 2018||Company Note||4SC AG (VSC-DE): Rising from the East|
|31 January 2018||Flash Note||4SC AG (VSC-DE): Pivotal trial passes first safety hurdle|
|11 December 2017||Initiation Note||4SC AG (VSC-DE): Orphan to best-in-class: HDACi come of age|
Edison Investment Research Limited
Jonas Peciulis, Ph.D.
280 High Holborn
London WC1V 7EE
Phone: +44 (0) 20 3077 5734
During the Q218 results call, 4SC management announced that with current funds, it plans to initiate some of its additional domatinostat trials including…
Yakult, 4SC’s development partner for resminostat in Japan, has reached two clinical development milestones. First, just two weeks after it joined…
Any opinions, estimates or forecasts made by these analysts on the performance of 4SC AG are not opinions, forecasts or predictions of 4SC AG or its management. By providing the list above, 4SC AG does not imply its endorsement of or concurrence with such information, conclusions or recommendations.
The list has been drawn up to the best of our knowledge. 4SC AG cannot give any assurance that the list represents a full overview of all analyst reports available on the market. This list may not be complete and may change from time to time. We update the list periodically, but undertake no obligation to do so.